Literature DB >> 17258672

Established treatments for acute ischaemic stroke.

Aslam M Khaja1, James C Grotta.   

Abstract

This article reviews the recommended management of patients presenting to accident and emergency departments with acute ischaemic stroke, and focuses on thrombolysis. The review includes initial management, recommended clinical, laboratory, and radiographic examinations. Appropriate general medical care, consisting of monitoring of oxygenation, fever, blood pressure, and blood glucose concentrations are examined. Criteria for thrombolysis with intravenous recombinant tissue plasminogen activator (rt-PA) are discussed. Complications of rt-PA therapy, such as haemorrhagic transformation and angio-oedema, are reviewed. An approach to management of rt-PA complications is outlined. Only a small percentage of acute ischaemic stroke patients meet criteria for rt-PA; therefore, alternative acute treatment strategies are also discussed. Acute medical and neurological complications in stroke patients are analysed, along with recommendations for treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258672     DOI: 10.1016/S0140-6736(07)60154-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion.

Authors:  Alexander Kunz; Takato Abe; Karin Hochrainer; Munehisa Shimamura; Josef Anrather; Gianfranco Racchumi; Ping Zhou; Costantino Iadecola
Journal:  J Neurosci       Date:  2008-02-13       Impact factor: 6.167

Review 2.  Alteplase for the treatment of acute ischaemic stroke: a NICE single technology appraisal; an evidence review group perspective.

Authors:  Michael Holmes; Sarah Davis; Emma Simpson
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

3.  Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.

Authors:  Fenghua Chen; Zhongfang Weng; Qinghai Xia; Catherine Cao; Rehana K Leak; Lihong Han; Jian Xiao; Steven H Graham; Guodong Cao
Journal:  Transl Stroke Res       Date:  2019-02-28       Impact factor: 6.829

4.  Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study.

Authors:  Estelle Rousselet; Anne Létondor; Bénédicte Menn; Yann Courbebaisse; Marie-Lise Quillé; Serge Timsit
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

Review 5.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

Review 6.  Cell adhesion molecules and ischemic stroke.

Authors:  Gokhan Yilmaz; D Neil Granger
Journal:  Neurol Res       Date:  2008-10       Impact factor: 2.448

7.  Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke.

Authors:  Laure Allard; Natacha Turck; Pierre R Burkhard; Nadia Walter; Anna Rosell; Marianne Gex-Fabry; Denis F Hochstrasser; Joan Montaner; Jean-Charles Sanchez
Journal:  Biomark Insights       Date:  2007-04-19

8.  Bilateral common carotid artery occlusion as an adequate preconditioning stimulus to induce early ischemic tolerance to focal cerebral ischemia.

Authors:  Lukas Julius Speetzen; Matthias Endres; Alexander Kunz
Journal:  J Vis Exp       Date:  2013-05-09       Impact factor: 1.355

9.  The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic.

Authors:  Takato Abe; Alexander Kunz; Munehisa Shimamura; Ping Zhou; Josef Anrather; Costantino Iadecola
Journal:  J Cereb Blood Flow Metab       Date:  2008-07-23       Impact factor: 6.200

10.  Blood glutathione S-transferase-π as a time indicator of stroke onset.

Authors:  Natacha Turck; Xavier Robin; Nadia Walter; Catherine Fouda; Alexandre Hainard; Roman Sztajzel; Ghislaine Wagner; Denis F Hochstrasser; Joan Montaner; Pierre R Burkhard; Jean-Charles Sanchez
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.